Related Experiment Video
Updated: Jul 19, 2026

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations
Martin Zenker1, Katarina Lehmann, Anna Leana Schulz
1Institute of Human Genetics, University of Erlangen-Nuremberg, Germany.
Background:
Noonan syndrome, cardio-facio-cutaneous syndrome (CFC) and Costello syndrome constitute a group of developmental disorders with an overlapping pattern of congenital anomalies. Each of these conditions can be caused by germline mutations in key components of the highly conserved Ras-MAPK pathway, possibly reflecting a similar pathogenesis underlying the three disorders. Germline mutations in KRAS have recently been identified in a small number of patients with Noonan syndrome and CFC.
Methods And Results:
260 patients were screened for KRAS mutations by direct sequencing. Overall, we detected KRAS mutations in 12 patients, including three known and eight novel sequence alterations. All mutations are predicted to cause single amino acid substitutions. Remarkably, our cohort of individuals with KRAS mutations showed a high clinical variability, ranging from Noonan syndrome to CFC, and also included two patients who met the clinical criteria of Costello syndrome.
Conclusion:
Our findings reinforce the picture of a clustered distribution of disease associated KRAS germline alterations. We further defined the phenotypic spectrum associated with KRAS missense mutations and provided the first evidence of clinical differences in patients with KRAS mutations compared with Noonan syndrome affected individuals with heterozygous PTPN11 mutations and CFC patients carrying a BRAF, MEK1 or MEK1 alteration, respectively. We speculate that the observed phenotypic variability may be related, at least in part, to specific genotypes and possibly reflects the central role of K-Ras in a number of different signalling pathways.
Insights
Germline KRAS mutations are linked to Noonan, cardio-facio-cutaneous (CFC), and Costello syndromes. These mutations cause a wide range of clinical features, highlighting K-Ras
Area of Science:
- Genetics
- Molecular Biology
- Developmental Biology
Background:
- Noonan, cardio-facio-cutaneous (CFC), and Costello syndromes share overlapping congenital anomalies.
- These disorders are linked to mutations in the Ras-MAPK pathway.
- Germline KRAS mutations have been identified in some Noonan and CFC patients.
Purpose of the Study:
- Investigate KRAS mutations in patients with Noonan, CFC, and Costello syndromes.
- Define the phenotypic spectrum associated with KRAS mutations.
- Compare clinical differences between KRAS mutation carriers and patients with mutations in other Ras-MAPK pathway genes.
Main Methods:
- Screened 260 patients for KRAS mutations using direct sequencing.
- Analyzed detected KRAS mutations for predicted amino acid substitutions.
- Correlated genotypes with clinical phenotypes.
Main Results:
- Detected KRAS mutations in 12 out of 260 patients (3 known, 8 novel alterations).
- Observed significant clinical variability, including features of Noonan, CFC, and Costello syndromes.
- Identified two patients meeting Costello syndrome criteria with KRAS mutations.
Conclusions:
- KRAS germline alterations are associated with a spectrum of related developmental disorders.
- KRAS mutations contribute to phenotypic variability, potentially influenced by specific genotypes.
- K-Ras plays a central role in multiple signaling pathways, explaining the observed clinical diversity.
Related Concept Videos
The Ras Gene
Ras is a superfamily...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
